ecrin-mdr-crcClinical2023Advanced Solid TumorNeoplasmsAdvanced Solid TumorNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/108891China9KRAS mutationPancreatic carcinomaNonsmall-cell lung cancer（NSCLC）Colorectal cancer（CRC）ECRIN MDRRecruitingfalseA Study of YL-17231 in Patients With Advanced Solid TumorsThis is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-17231 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-17231 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.2023-09-15108891NCT06078800